Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen is eligible to receive up to US$365 million, including an upfront payment and development, regulatory...
Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points Superior PK: Subcutaneous administration of ADCs combined with ALT-B4...